Our guest speaker Lee Gravatt Wilke, MD, Senior Medical Director at the University of Wisconsin School of Medicine and Public Health, explains the current state of vaccine clinical trials in breast cancer followed by a review of the STEMVAC trial, design of the vaccine, and the current state of the accrual and next steps.
Key Takeaways from Webinar Viewers:
- Vaccines are more complex than drugs in their development due to the three components (finding protein, packaging it, and finding the right immuno response) and may take longer to develop.
- Clinical trials are important and hope patient navigators and advocates can explain the importance of clinical trials and their pros and cons help ease the fears of participation.
- Vaccines are gender nonspecific and cater to the cancer’s specificity – it would be non-binary.
- Vaccines are being tested in cancers and look on clinicaltrials.gov if you are interested in this approach.
